Dyslipidemia Therapeutics: A Global Strategic Business Report
San Jose, CA (PRWEB) March 30, 2010
Metabolic disorders affect millions of people around the world. Dyslipidemia is one such metabolic disease, which affects around 300 million people across the US, Western Europe and Japan. Dyslipidemia is a disorder characterized by high lipid levels in blood, caused by lifestyle and diet. As people grow old, the lipoprotein level increases, which causes a slight increase in lipids, especially LDL cholesterol. Mixed Dyslipidemia is one of the segments of the dyslipidemia market offering large scale opportunities.
The market for dyslipidemia therapeutics is dominated by the statins class of drugs. The market for Statins is expected to face significant change owing to expiration of patent protection of some of the major branded blockbuster drugs, generic erosion, as well as increasing use of fixed-dose combination therapies. The years 2010 and 2011 are expected to witness maximum genericization of the statin drug class. Pfizer's Lipitor patent protection is scheduled to expire in 2011. Non-Statins represent the fastest growing product segment. The segment, which includes fibrates, omega-3 esters and niacin, is estimated to account for a market share of 17% by the year 2015. Meanwhile, the leading players can tap the market potential by focusing on novel drug combinations as well as improving patient sub-group targeting. Combination therapies are expected to witness a rise in demand as such therapies are capable of managing various parameters of lipid profile in patients suffering from mixed dyslipidemia.
The United States and Europe dominate the world Dyslipidemia Therapeutics market as stated by the new market research report on Dyslipidemia Therapeutics. Over 100 million adult patients suffer from dyslipidemia across the US, of which around 34 million suffer from mixed dyslipidemia. The patient population of mixed dyslipidemia is expected to increase and become a major segment of the dyslipidemic population. Europe is the third most important market for lipid regulators after the US and Japan.
The market for dyslipidemia drugs is highly competitive. Pfizer dominates the market for dyslipidemia therapeutics while Abbott is the leading company in the non-statins market. Other prominent players in the market include AstraZeneca, PLC, GlaxoSmithKline, Inc.
Merck & Co., Inc., Mylan, Inc., Novartis AG and Teva Pharmaceutical Industries Ltd.
The report titled "Dyslipidemia Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, competitive scenario, technological overview, product introductions/innovations, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Japan, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Dyslipidemia_Therapeutics_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com/